Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ATEA PHARMACEUTICALS, INC.

(AVIR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Atea Pharma Shares Drop 16% After Collaboration With Roche Terminated

11/17/2021 | 10:11am EST

By Chris Wack

Atea Pharmaceuticals Inc. shares fell 16% to $9.53 after the company said its strategic collaboration with Roche to develop AT-527 to treat Covid-19 is ending in February.

The biopharmaceutical company said the rights and licenses granted to Roche will be returned to Atea, which will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.

Atea said that as of Sept. 30 it had cash and cash equivalents of $839.7 million, with a cash runway through 2023.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

11-17-21 1011ET

Stocks mentioned in the article
ChangeLast1st jan.
ATEA PHARMACEUTICALS, INC. 0.00% 7.3 Delayed Quote.-18.34%
ROCHE HOLDING AG 0.79% 365 Delayed Quote.-3.72%
All news about ATEA PHARMACEUTICALS, INC.
01/12Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Atea Pharmaceuticals, Inc. ..
BU
01/10ATEA PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (..
AQ
01/07SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atea ..
PR
01/07Atea Pharmaceuticals Highlights Strategic Priorities for 2022
GL
01/07Atea Pharmaceuticals Highlights Strategic Priorities for 2022
GL
01/07Atea Pharmaceuticals, Inc. Provides an Update on the Company’s Clinical Developmen..
CI
01/07NORTH AMERICAN MORNING BRIEFING : Stock Futures -2-
DJ
01/06Morgan Stanley Downgrades Atea Pharmaceuticals to Underweight From Equal Weight, Adjust..
MT
01/03Atea Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference
GL
2021ATEA PHARMACEUTICALS, INC.(NASDAQGS : AVIR) added to NASDAQ Biotechnology Index
CI
More news
Analyst Recommendations on ATEA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 259 M - -
Net income 2021 20,0 M - -
Net cash 2021 658 M - -
P/E ratio 2021 34,3x
Yield 2021 -
Capitalization 607 M 607 M -
EV / Sales 2021 -0,20x
EV / Sales 2022 3,62x
Nbr of Employees 56
Free-Float -
Chart ATEA PHARMACEUTICALS, INC.
Duration : Period :
Atea Pharmaceuticals, Inc. Technical Analysis Chart | AVIR | US04683R1068 | MarketScreener
Technical analysis trends ATEA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 7,30 $
Average target price 13,75 $
Spread / Average Target 88,4%
EPS Revisions
Managers and Directors
Jean-Pierre Sommadossi Chairman, President & Chief Executive Officer
Andrea J. Corcoran Chief Financial Officer, Secretary & EVP-Legal
Maria Arantxa Horga Chief Medical Officer
Keith Pietropaolo Senior Vice President-Clinical Operations
Claudio Avila Senior Vice President-Medical Affairs
Sector and Competitors